iRhythm is a leading digital health care company redefining the way cardiac arrhythmias are clinically diagnosed. The company combines wearable biosensor devices worn for up to 14 days and cloud-based data analytics with powerful proprietary algorithms that distill data from millions of heartbeats into clinically actionable information. The company believes improvements in arrhythmia detection and characterization have the potential to change clinical management of patients.
650 Townsend St Ste 500
San Francisco, California 94103-6227
Phone: 14156325700
www.irhythmtech.com
iRhythm Technologies Inc (IRTC) Q2 2024 Earnings Call Transcript Highlights: Strong Revenue Growth Amid Regulatory Challenges
Q2 2024 iRhythm Technologies Inc Earnings Call Transcript
No summary available.
The following slide deck was published by iRhythm Technologies, Inc.
iRhythm Technologies (NASDAQ: IRTC ) just reported results for the second quarter of 2024. iRhythm Technologies reported earnings per share of -61 cents. This was above the analyst estimate for EPS of -89 cents. The company reported revenue of $148.05 million. This was 1.28% better than the analyst estimate for revenue of $146.17 million. InvestorPlace Earnings is a project that leverages data from TradeSmith to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at editor@investorplace.com. More From InvestorPlace Legendary Investor Predicts: “Forget AI… THIS Technology Is the Future” The post IRTC Stock Earnings: iRhythm Technologies Beats EPS, Beats Revenue for Q2 2024 appeared first on InvestorPlace .
SAN FRANCISCO, Aug. 01, 2024 (GLOBE NEWSWIRE) -- iRhythm Technologies, Inc . (NASDAQ: IRTC), a leading digital health care company focused on creating trusted solutions that detect, predict, and prevent disease, announced today that Brice Bobzien, Chief Financial Officer, will step down for personal reasons effective August 31, 2024. He will be succeeded by Daniel Wilson, iRhythm’s current Executive Vice President of Corporate Development and Investor Relations. Mr. Bobzien has served as the CFO since 2022, and he will continue to serve the Company in an advisory capacity into 2025 following the succession to ensure a smooth transition.
https://www.investing.com/news/company-news/irhythm-technologies-executive-sells-148k-in-stock-93CH-3507710
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page . Wolfe Research analyst Mike Polark upgraded the rating for iRhythm Technologies, Inc . (NASDAQ: IRTC ) from Peer Perform to Outperform and announced a price target of $115. iRhythm Technologies shares gained 2.5% to close at $98.16 on Wednesday. See how other analysts view this stock . Evercore ISI Group analyst John Pancari upgraded Bread Financial Holdings, … Full story available on Benzinga.com
https://www.investing.com/news/company-news/wolfe-research-upgrades-irhythm-technologies-stock-on-growth-prospects-93CH-3489535
iRhythm Technologies launches advanced automation phase to enhance PCB testing for Zio monitors, aiming for reduced costs and increased global service capacity.